Back to Search
Start Over
Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.
- Source :
-
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Nov 01; Vol. 32 (11), pp. 762. Date of Electronic Publication: 2024 Nov 01. - Publication Year :
- 2024
-
Abstract
- Purpose: Scalp cooling therapy (SCT) improves chemotherapy-induced alopecia (CIA), but there are few published data about its efficacy in an Asian-predominant population. We report our tertiary institution experience of SCT in patients with breast or gynaecological cancers undergoing chemotherapy.<br />Methods: The Paxman scalp cooling system was employed for eligible women with breast or gynaecological cancers receiving anthracycline or taxane-based chemotherapy. Only patients with Grade (G) 0-1 alopecia by common terminology criteria for adverse events (CTCAE) version 4.0 were eligible initially, but patients with G2 alopecia were later included in the study. SCT was performed at each chemotherapy cycle, commencing 30 min prior to and continuing up to 90 min after completion of the drug infusion. Patients were assessed at the start and end of each session for hair preservation (defined as G0-2 alopecia) and comfort level of SCT (rated on a 5-point visual scale). The primary end point was success of hair preservation or hair regrowth after completion of all cycles of chemotherapy.<br />Results: Eighty-three patients were enrolled over a period of 18 months from December 2017 to October 2019, with a total of 510 scalp cooling cycles performed. 94.0% (nā=ā78) of patients reported a comfort score of 3 and above, indicating that the procedure was comfortable, upon a 5-point visual scale. Patients receiving weekly paclitaxel had highest success in hair preservation at 76.7% (23/30 patients), with a lower rate of hair preservation observed for the 3 weekly paclitaxel regimen (50%, 2/4 patients). In contrast, only 1 patient (5.3%, 1/19 patients) who underwent chemotherapy with anthracycline and cyclophosphamide achieved hair preservation.<br />Conclusion: SCT is well tolerated in an Asian-predominant population. Among women with breast or gynaecological cancers receiving taxane and/or anthracycline based chemotherapy, those who underwent SCT were about 50% more likely to achieve hair preservation or hair regrowth, as compared to historical controls.<br /> (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Subjects :
- Humans
Female
Middle Aged
Adult
Aged
Tertiary Care Centers
Antineoplastic Agents adverse effects
Antineoplastic Agents administration & dosage
Bridged-Ring Compounds adverse effects
Bridged-Ring Compounds administration & dosage
Bridged-Ring Compounds therapeutic use
Anthracyclines adverse effects
Anthracyclines administration & dosage
Taxoids adverse effects
Taxoids administration & dosage
Alopecia chemically induced
Alopecia prevention & control
Breast Neoplasms drug therapy
Hypothermia, Induced methods
Genital Neoplasms, Female drug therapy
Genital Neoplasms, Female therapy
Scalp
Subjects
Details
- Language :
- English
- ISSN :
- 1433-7339
- Volume :
- 32
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 39482416
- Full Text :
- https://doi.org/10.1007/s00520-024-08940-2